An editorial or commentary titled 'Bremelanotide: the female Viagra?' examining whether bremelanotide deserves comparison to sildenafil as a landmark sexual dysfunction treatment. Discusses the pharmacological differences, efficacy expectations, and broader implications of having a centrally acting option for women with HSDD.